AMGEN's EPOGEN R&D COSTS WERE OVER 50% OF TOTAL COMPANY R&D SPENDING, CEO RATHMANN TELLS PRYOR HEARING; CITES IMPORTANCE OF INVESTOR RETURN

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".